493 related articles for article (PubMed ID: 18264934)
21. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
22. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
23. The Fabry cardiomyopathy: models for the cardiologist.
Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
[TBL] [Abstract][Full Text] [Related]
25. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
26. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
[TBL] [Abstract][Full Text] [Related]
27. [Current management of Fabry disease].
Cochat P; Liutkus A; Dubourg L; Levade T
Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
[TBL] [Abstract][Full Text] [Related]
28. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
29. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
[TBL] [Abstract][Full Text] [Related]
30. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
31. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
34. Enzyme replacement therapy in Fabry disease: clinical implications.
Breunig F; Knoll A; Wanner C
Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
[TBL] [Abstract][Full Text] [Related]
35. Renal ultrastructural findings in Anderson-Fabry disease.
Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
[TBL] [Abstract][Full Text] [Related]
36. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
39. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
40. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]